Painless abortion
Conditions
Interventions
AC 0.5 group:Patients in the AC 0.5 group received a mixture of 0.05 mL/kg (drug preparation method: uniformly mix 1 mL of alfentanil (0.5 mg) and 19 mL of propofol (47.5 mg) in a 20 mL syringe). to
AC 0.75 group:Patients in the AC 0.75 group received a mixture of 0.05 mL/kg (drug preparation method: uniformly mix 1.5 mL of alfentanil (0.75 mg) and 18.5 mL of propofol (46.25 mg) in a 20 mL syring
AC1.0 group:Patients in the AC 1.0 group received 0.05 mL/kg of the mixture (drug preparation method: uniformly mix 2 mL of alfentanil (1.0 mg) and 18 mL of propofol (45 mg) in a 20 mL syringe), follo
ACS group:Patients in the ACS group received the mixture (drug preparation method: uniformly mix 1.5 mL of alfentanil at 0.75 mg with 18.5 mL of propofol at 46.25 mg in a 20 mL syringe) at a dose of 0
PCS group:Patients in the PCS group continuously pressed the handle, with medication delivered via an extension tube and three-way stopcock through an infusion pump. The infusion pump was set to an in
Sponsors
The Second Hospital of Dalian Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.Clearly understand and voluntarily participate in the study by signing the informed consent form. 2.After confirming intrauterine pregnancy through pregnancy tests and ultrasound examination, voluntarily undergo a painless abortion procedure. 3. Be at least 18 years of age, have a body mass index (BMI) between 18.5 and 28 kg/m^2, and be classified as ASA (American Society of Anesthesiologists) physical status class II.
Exclusion criteria
Exclusion criteria: 1. Individuals with psychiatric disorders such as schizophrenia or mania; those on long-term medication with anesthetics, Schedule I controlled substances, or Schedule II controlled substances; individuals with cognitive impairment or hearing impairment; and those unable to cooperate with the examination. 2.Patients with significant preoperative respiratory dysfunction, such as obstructive sleep apnea syndrome, acute respiratory tract infection, acute exacerbation of chronic obstructive pulmonary disease, or uncontrolled asthma. Patients assessed as having difficult airway management: Modified Mallampati Score of III or IV. 3.Patients with significant preoperative circulatory dysfunction, such as New York Heart Association (NYHA) functional class III or IV, unstable angina, myocardial infarction within 6 months prior to surgery, third-degree atrioventricular block, or moderate to severe valvular heart disease. 4.Patients with significant preoperative liver or kidney disease and coagulation disorders. 5.Patients with limited head extension, cervical spine immobility, ankylosing spondylitis, or myasthenia gravis. 6. Patients with a history of long-term smoking, alcohol abuse, or diabetes. 7.Patients with known allergy or contraindication to the study drugs (e.g., alfentanil hydrochloride injection, propofol injection) or their components. 8. Patients currently participating in other clinical trials. 9.Patients deemed unsuitable for this trial by the investigator. 10. Patients who voluntarily withdraw from the trial, refuse participation, or decline follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of mandibular displacement;Time points (including induction time, surgical time, recovery time, and PACU recovery time);Dosage; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sedation success rate;Perioperative vital signs and OAA/S score;Pain Scores (Including injection pain at anesthesia initiation, postoperative uterine contraction pain, postoperative day 1 uterine contraction pain);Satisfaction scores of gynecologists, anesthesiologists, and patients; | — |
Countries
China
Contacts
Public ContactLiu Jie
The Second Hospital of Dalian Medical University
Outcome results
None listed